Utebzi (tebipenem pivoxil): FDA approval, pivotal trial and safety
Approved
Type
New molecular entity · Oral
FDA-approved use
To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment optionsWording from FDA's list of novel approvals.
FDA review
Priority review
Company
GlaxoSmithKline
Application
NDA 215960
Specialty
Infectious Disease
At a glance
Utebzi (tebipenem pivoxil) is an oral penem antibacterial approved in June 2026 for complicated urinary tract infections, including pyelonephritis, in adults with limited or no alternative oral options. In the pivotal trial of 1690 hospitalized patients, it was noninferior to intravenous imipenem-cilastatin on a composite of clinical cure and microbiological response. Main safety points are hypersensitivity, seizures, carnitine depletion and C. difficile infection; there is no boxed warning.
What it is and how it works
Tebipenem pivoxil is a prodrug that is converted to tebipenem, a carbapenem-class antibacterial. It is given by mouth. Most carbapenems are given intravenously, so this offers an oral option for patients with resistant Enterobacterales who would otherwise need IV therapy.
Global, randomized, double-blind, double-dummy, noninferiority phase 3 trial of 7 to 10 days of therapy, with renal dose adjustment.
Patients
1690 hospitalized adults with cUTI or pyelonephritis; the microbiological ITT population had 929 patients (median age 68 years, 58% female, 7% with bacteremia at baseline).
Compared with
Intravenous imipenem-cilastatin.
Primary endpoint
Composite of clinical cure and microbiological response at the test-of-cure visit (day 17 ± 2) in the microbiological ITT population.
Result
The trial showed noninferiority of Utebzi to imipenem-cilastatin on the composite response. Effect size, confidence interval and P value are not given in the available label text.
Other results
Clinical cure and microbiological response were assessed separately at the test-of-cure visit; the available text does not give the values.
Safety in the trial
843 patients received Utebzi and 844 received imipenem-cilastatin, for a median of 7.5 and 7.6 days. Adverse reactions led to discontinuation in 0.6% (5/843) with Utebzi and 0.8% (7/844) with imipenem-cilastatin.
How does Utebzi (tebipenem pivoxil) compare with the alternatives (Fluoroquinolones, Trimethoprim-sulfamethoxazole, Oral cephalosporins and other beta-lactams) for complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options? Summarize head-to-head and indirect evidence, efficacy, safety and where each fits, with citations.
Phase 3, international, double-blind, double-dummy noninferiority trial with 1:1 randomization to 7 to 10 days of therapy (up to 14 days with bacteremia). Noninferiority margin 12.5%. This trial used the hydrobromide salt of the drug.
Patients
1372 hospitalized adults with cUTI or acute pyelonephritis; 868 (63.3%) were in the microbiologic ITT population.
Compared with
Intravenous ertapenem.
Primary endpoint
Overall response (clinical cure plus favorable microbiologic response) at test of cure (day 19, ±2 days) in the microbiologic ITT population.
Result
Overall response occurred in 58.8% (264/449) with tebipenem and 61.6% (258/419) with ertapenem; weighted difference -3.3 percentage points (95% CI -9.7 to 3.2). Noninferiority was met.
Other results
Clinical cure was 93.1% with tebipenem and 93.6% with ertapenem (weighted difference -0.6 percentage point; 95% CI -4.0 to 2.8). Most microbiologic failures were asymptomatic recurrent bacteriuria. Subgroup analyses supported the primary result.
Safety in the trial
Adverse events occurred in 25.7% with tebipenem and 25.6% with ertapenem. The most common were mild diarrhea and headache.
There is no boxed warning. The label warns of serious and occasionally fatal hypersensitivity reactions, so assess for prior reactions to carbapenems, penicillins, cephalosporins or other beta-lactams. Seizures and other CNS reactions can occur. Avoid use with valproic acid or divalproex sodium, since it may lower their levels and raise the risk of breakthrough seizures. Because the drug contains pivalate, use beyond the recommended duration may cause carnitine deficiency. C. difficile infection and a false positive newborn screen for isovaleric acidemia after treatment in pregnancy are also described. The most common adverse reactions (1% or more) were diarrhea, headache, nausea, abdominal pain, raised liver enzymes and C. difficile infection.
What it competes with
Complicated UTI is treated according to culture and susceptibility data. Options include oral agents when the isolate is susceptible and intravenous therapy for resistant organisms or more severe illness.
FluoroquinolonesOral option for susceptible isolates, but resistance limits use and they carry class warnings.
Trimethoprim-sulfamethoxazoleOral choice when the isolate is known to be susceptible.
Oral cephalosporins and other beta-lactamsUsed for susceptible organisms, usually after initial therapy or for milder disease.
Intravenous carbapenems (such as ertapenem, imipenem-cilastatin)Standard for resistant Enterobacterales, including ESBL producers, but require IV access.
AminoglycosidesParenteral option for some resistant infections, with kidney and ear toxicity concerns.
Bottom line for clinicians
Utebzi is for adults with cUTI or pyelonephritis due to the listed susceptible organisms who have few or no oral alternatives. It may allow oral therapy where IV carbapenems would otherwise be needed. Weigh the seizure risk, the valproate interaction, the carnitine warning with limited treatment duration, and the need to guide use by susceptibility data.
Dosing, contraindications and full warnings are in the prescribing information.
New FDA approvals in your inbox
The free 2 Minute Medicine Daily Brief: new approvals, landmark trials and the day's top studies, written by physicians.
Your subscription opens securely in a new tab.
Last updated October 28, 2026 by 2 Minute Medicine.
For healthcare professionals. A summary of public FDA documents and published trials, not medical advice. Check the full prescribing information before prescribing.
Get the app